Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

BACKGROUND: The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contribute to the survival and development of resistance in response to therapy. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Tejaswini P., Choi, Dong S., Anselme, Ann C., Qian, Wei, Chen, Wen, Lantto, Johan, Horak, Ivan D., Kragh, Michael, Chang, Jenny C., Rosato, Roberto R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227035/
https://www.ncbi.nlm.nih.gov/pubmed/32414394
http://dx.doi.org/10.1186/s13058-020-01280-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227035/
https://www.ncbi.nlm.nih.gov/pubmed/32414394
http://dx.doi.org/10.1186/s13058-020-01280-z

Ejemplares similares